IL10 and peeling skin syndrome: In the present study, there were no differences between CD19+/CD38hi/CD24hi/CXCR4+/IL-10+ levels in pSS patients and controls, suggesting that, at least at systemic level, these cells are not affected by clinical or serologic pSS activity: CD19+/CD38hi/CD24hi/CXCR7+/IL-10+ regulatory B cells were increased in pSS patients with clinically inactive disease compared to patients with clinically active disease and healthy controls.